Belite Bio Raises $275 Million in Upsized Private Placement to Advance Retinal Disease Therapies
Key Insights
Belite Bio (search) secured up to $275 million in private placement financing led by RA Capital Management (search), with $125 million upfront and potential additional $150 million from warrant exercises.
The funding will support commercialization preparation and advancement of tinlarebant, the company's lead therapeutic targeting Stargardt disease (search) and geographic atrophy (search) in dry age-related macular degeneration (search).
Leading healthcare investors including Eventide Asset Management (search), Marshall Wace (search), RTW Investments (search), Soleus Capital (search) and Vestal Point Capital (search) participated in the financing round.
Belite Bio (search) has successfully closed a substantial private placement financing that could reach up to $275 million, marking one of the largest funding rounds for a clinical-stage company focused on retinal degenerative diseases (search). The transaction, led by RA Capital Management (search) with participation from prominent healthcare investors, provides $125 million in immediate funding with the potential for an additional $150 million through warrant exercises.
Major Healthcare Investors Back Retinal Disease Pipeline
The private placement in public equity (PIPE) financing attracted leading institutional investors including Eventide Asset Management (search), Marshall Wace (search), RTW Investments (search), Soleus Capital (search) and Vestal Point Capital (search). Under the terms of the agreement, Belite Bio (search) will issue 1,953,124 ordinary shares and accompanying warrants at a purchase price of $64.00 per share and warrant unit.
The warrants are immediately exercisable at $76.80 per share, representing a 20% premium to the purchase price, and will expire two years from issuance. This structure provides investors with immediate equity participation while offering the company potential additional capital if the warrants are exercised.
Tinlarebant Development and RBP4 Inhibition Strategy
Tom Lin, Chairman and Chief Executive Officer of Belite Bio (search), emphasized the significance of investor confidence in the company's lead therapeutic tinlarebant and its novel mechanism of action. "We view this investment as validation of RBP4 (search) inhibition as a mechanism of action and more generally of our scientific approach to treating these diseases," Lin stated.
The funding will enable Belite Bio (search) to advance tinlarebant through clinical development for two primary indications: Stargardt disease (search) and geographic atrophy (search) in advanced dry age-related macular degeneration (search). Both conditions represent significant unmet medical needs in ophthalmology, with limited treatment options currently available to patients.
Strategic Use of Proceeds for Commercialization
Belite Bio (search) intends to allocate the net proceeds toward commercialization preparation, working capital, and general corporate purposes. This strategic deployment of capital positions the company to advance its clinical programs while building the infrastructure necessary for potential future product launches.
The company's focus on degenerative retinal diseases aligns with growing investor interest in ophthalmology therapeutics, particularly those targeting previously untreatable conditions. The substantial funding round reflects confidence in Belite Bio (search)'s scientific approach and the potential market opportunity for effective treatments in this therapeutic area.
Transaction Details and Timeline
Morgan Stanley (search) served as the sole placement agent for the private placement, which is expected to close on or about September 9, 2025, subject to customary closing conditions. The securities are being issued under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Belite Bio (search) agreeing to file a registration statement for the resale of the ordinary shares and warrant shares.
This financing follows a previous $15 million direct offering announced earlier in 2025, demonstrating continued investor appetite for the company's therapeutic programs and commercial potential in the retinal disease space.